416
Participants
Start Date
May 1, 2019
Primary Completion Date
November 15, 2019
Study Completion Date
November 15, 2019
Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium
"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 0.375 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
Ensifentrine (formerly RPL554) 0.75 mg twice daily plus placebo, in addition to tiotropium
"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 0.75 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
Ensifentrine (formerly RPL554) 1.5 mg twice daily plus placebo, in addition to tiotropium
"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 1.5 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
Ensifentrine (formerly RPL554) 3.0 mg twice daily plus placebo, in addition to tiotropium
"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 3.0 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
Ensifentrine (formerly RPL554) placebo twice daily, in addition to tiotropium
"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● Placebo twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
Clinical Research of Gastonia, Gastonia
American Health Research, Charlotte
Research Carolina of Huntersville, Huntersville
Clinical Research of Lake Norman, Mooresville
Fusion Clinical Research of Spartanburg, LLC, Spartanburg
Spartanburg Medical Research, Spartanburg
Vitalink Research-Spartanburg, Spartanburg
VitaLink Research-Gaffney, Gaffney
VitaLink Research - Union, Union
Lowcountry Lung and Critical Care, PA, Charleston
Clinical Research of Charleston, Mt. Pleasant
VitaLink Research-Greenville, Greenville
VitaLink Research-UPSTATE, Greenville
Vitalink Research - Anderson, Anderson
VitaLink Research - Easley, Easley
Vitalink Research-Seneca, Seneca
Piedmont Research Partners, LLC, Fort Mill
Clinical Research of Rock Hill, Rock Hill
VitaLink Research - Hamilton Mill, Dacula
Gwinnett Biomedical Research, Lawrenceville
VitaLink Research - Duluth, Duluth
Vitalink, Winder
IACT Health, Rincon
Columbus Regional Research Institute, Columbus
Progressive Medical Research, Port Orange
Peninsula Research, Ormond Beach, LLC, Ormond Beach
Florida Pulmonary Research Institute, LLC, Winter Park
Clinical Trials of Florida, LLC, Miami
Meris Clinical Research, Brandon
Pasadena Center for Medical Research, LLC, St. Petersburg
Clinical Research of West Florida, Clearwater
VitaLink-Columbia, Columbia
Medsol Clinical Research Center, Inc, Port Charlotte
Pulmonary Disease Specialists, PA d/b/a PDS Research, Kissimmee
Cities Research Center, Fridley
Medical Research of Central Florida, LLC, Leesburg
Pinnacle Research Group, LLC, Anniston
New Phase Research & Development, Knoxville
Aventiv Research, Inc, Dublin
Aventiv Research, Inc, Columbus
New Horizons Clinical Research, Cincinnati
Pulmonary Research Institute of Southeast Michigan, Farmington Hills
Metroplex Pulmonary and Sleep Center, McKinney
DCOL Center for Clinical Research, Longview
FMC Science, LLC, Lampasas
Innovative Clinical Research, Lafayette
Southern California Institute For Respiratory Diseases, Inc., Los Angeles
California Research Medical Group, Inc, Fullerton
Crisor, LLC, Medford
Genesis Clinical Research and Consulting, LLC, Fall River
Iqvia Pty Ltd
INDUSTRY
LGC Limited
INDUSTRY
Verona Pharma plc
INDUSTRY